Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
-
- Elias Jabbour
- The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Hagop M. Kantarjian
- The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Giuseppe Saglio
- University of Torino, Ospedale San Luigi Gonzaga, Orbassano-Torino, Italy;
-
- Juan Luis Steegmann
- Hospital de la Princesa, Madrid, Spain;
-
- Neil P. Shah
- University of California, San Francisco School of Medicine, San Francisco, CA;
-
- Concepción Boqué
- Department of Clinical Hematology, Institut Català d’Oncologia, Hospitalet de Llobregat, Barcelona, Spain;
-
- Charles Chuah
- Singapore General Hospital and Duke-National University of Singapore Graduate Medical School, Singapore;
-
- Carolina Pavlovsky
- Fundación Para Combatir la Leucemia, Angelica Ocampo Hospitalization and Clinical Research Center, Buenos Aires, Argentina;
-
- Jiří Mayer
- University Hospital Brno and Central European Institute of Technology Masaryk University, Brno, Czech Republic;
-
- Jorge Cortes
- The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- Michele Baccarani
- University of Bologna, Bologna, Italy;
-
- Dong-Wook Kim
- The Catholic University of Korea, Seoul, Korea;
-
- M. Brigid Bradley-Garelik
- Bristol-Myers Squibb, Wallingford, CT;
-
- Hesham Mohamed
- Bristol-Myers Squibb, Princeton, NJ; and
-
- Mark Wildgust
- Bristol-Myers Squibb, Princeton, NJ; and
-
- Andreas Hochhaus
- Universitätsklinikum Jena, Jena, Germany
Description
<jats:title>Key Points</jats:title> <jats:p>In a 3-year follow-up of the DASatinib versus Imatinib Study In treatment-Naive CML patients trial, first-line dasatinib resulted in faster and deeper responses compared with imatinib. Deeper responses at 3, 6, and 12 months were associated with better 3-year progression-free survival and overall survival.</jats:p>
Journal
-
- Blood
-
Blood 123 (4), 494-500, 2014-01-23
American Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1360292619829029888
-
- ISSN
- 15280020
- 00064971
-
- Data Source
-
- Crossref